Hofbieber/Munich (DE), Antwerp (BE) — Gimv invests in the Apra­xon Group, a leading home­care company focu­sed on wound care in Germany. The tran­sac­tion, which has alre­ady been comple­ted, is part of a joint growth plan with the company’s foun­der and CEO, Oliver Pokrze­win­ski, who will conti­nue to be a key share­hol­der in the company.

Apra­xon, (Hofbie­ber (DE) — apraxon.com), offers high-quality wound care for (mainly elderly) people with chro­nic wounds in the home­care sector. Typi­cal wound indi­ca­ti­ons are decu­bi­tus, diabe­tic foot or ulcus cruris. In this context, the company acts as a link between pati­ents, doctors, nursing service/home and the health insu­rance companies.

Due to its high degree of specia­liza­tion, Apra­xon provi­des a conti­nuously high quality of medi­cal care and is able to tailor the treat­ment process to the indi­vi­dual needs of each pati­ent. In a market with steadily rising pati­ent numbers, driven prima­rily by demo­gra­phic change, specia­li­zed medi­cal care is beco­ming incre­asingly important. The services are reim­bur­sed by health insu­rance compa­nies, for which Apra­xon has been a relia­ble part­ner for many years.

“I am convin­ced that Gimv is the right part­ner to realize the company’s growth ambi­ti­ons and expand Apraxon’s presence in Germany,” said Oliver Pokrze­win­ski, Mana­ging Direc­tor and CEO of Apraxon.

“Thanks to Apraxon’s clear commit­ment to quality, the above-average quali­fi­ca­tion of their nursing staff and their highly digi­ta­li­zed and scalable proces­ses, we are convin­ced that Apra­xon is the right plat­form to build a true market leader in German wound care. We are very much looking forward to support­ing Mr. Pokrze­win­ski and the entire Apra­xon team in imple­men­ting their ambi­tious growth plans,” says Phil­ipp v. Hammer­stein, Part­ner at Gimv in the Health & Care team in Munich.

The new invest­ment is alre­ady Gimv’s fifth acqui­si­tion in the German-spea­king health­care market within the last four years. Gimv curr­ently holds a total of 23 invest­ments in compa­nies in the health­care and life scien­ces sector. With this acqui­si­tion, Gimv once again under­lines its posi­tion as one of the most active Euro­pean inves­tors in the health­care indus­try and its ambi­tion to posi­tively contri­bute to the United Nati­ons goals; in this case “Health and Well­be­ing”. The Gimv port­fo­lio also includes seve­ral hospi­tal and prac­tice groups as well as medi­cal tech­no­logy and biotech companies.

ABOUT GIMV
Gimv is a Euro­pean invest­ment company with 40 years of expe­ri­ence in private equity. The company is listed on Euron­ext Brussels, curr­ently mana­ges around EUR 2.0 billion and curr­ently invests in 55 port­fo­lio compa­nies, which toge­ther gene­rate reve­nues of more than EUR 2.5 billion and employ 14,000 people. Gimv’s aspi­ra­tion to make a posi­tive value contri­bu­tion to society is reflec­ted, among other things, in the recently successfully laun­ched Sustainable Bond.

Gimv iden­ti­fies inno­va­tive, leading compa­nies with high growth poten­tial and supports them sustain­ably on their way to market leader­ship. Each of the four invest­ment plat­forms Consu­mer, Health & Care, Smart Indus­tries and Sustainable Cities is mana­ged by a dedi­ca­ted and compe­tent team, each based in Gimv’s home markets — Bene­lux, France and DACH — and supported by an exten­sive inter­na­tio­nal network of experts.